IP Library Patent Application 14613532
Patent Application
App. No. 14/613,532

Composition for Intravascular Delivery of Therapeutic Composition

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/613,532
Filed
Feb 4, 2015
Art Unit
1611
USPC
604/101.02
Abstract

The present invention relates to a pharmaceutical composition for intravascular delivery of a therapeutic agent, such as paclitaxel, rapamycin, or an analog thereof. The composition includes the therapeutic agent and a biocompatible solvent, such as glycofurol. The composition can aid tissue penetration by the therapeutic agent. A catheter assembly that protects the pharmaceutical composition from the surroundings can be used for its intravascular delivery.

Claims (26)

1 - 14 . (canceled)

15 . A pharmaceutical composition comprising about 1 to about 50 wt-% therapeutic agent and about 50 to about 99 wt-% biocompatible solvent; wherein:

the therapeutic agent comprises paclitaxel; and

the biocompatible solvent comprises glycofurol, wherein the biocompatible solvent delivers the therapeutic agent within a tissue.

16 . The composition of claim 15 , comprising about 5 to about 40 wt-% therapeutic agent and about 60 to about 95 wt-% biocompatible solvent.

17 . The composition of claim 15 , comprising about 2 to about 20 wt-% therapeutic agent and about 80 to about 98 wt-% biocompatible solvent.

18 . The composition of claim 15 , comprising about 5 to about 10 wt-% therapeutic agent and about 90 to about 95 wt-% biocompatible solvent.

19 . The composition of claim 15 , comprising about 10 to about 30 wt-% therapeutic agent and about 70 to about 90 wt-% biocompatible solvent.

20 . The composition of claim 15 , comprising about 5 to about 15 wt-% therapeutic agent and about 85 to about 95 wt-% biocompatible solvent.

21 . The composition of claim 15 , comprising about 10 to about 20 wt-% therapeutic agent and about 80 to about 90 wt-% biocompatible solvent.

22 . The composition of claim 15 , comprising about 20 to about 30 wt-% therapeutic agent and about 70 to about 80 wt-% biocompatible solvent.

23 . An intravascular catheter comprising a reservoir; the reservoir containing a pharmaceutical composition comprising about 1 to about 50 wt-% biodegradable polymer and about 50 to about 99 wt-% glycofurol.

24 . The catheter of claim 23 , wherein a third lumen defines the reservoir.

25 . The catheter of claim 23 , wherein two balloons define the reservoir.

26 . The catheter of claim 23 , wherein the catheter is a catheter assembly comprising:

an inner expandable and collapsible structure, an outer expandable and collapsible structure, the inner and outer expandable and collapsible structures each being configured to expand between a contracted state and a dilated state;

the inner and outer expandable and collapsible structures defining a reservoir therebetween, the reservoir being configured to contain a benefit composition;

the outer expandable and collapsible structure defining openings, the openings being configured to be closed when the assembly is in the contracted state and open when the assembly is in the dilated state; when open, the openings provide fluid communication from the cavity to surroundings of the assembly.

27 . A method of delivering a biodegradable polymer to a site in a body, the method comprising:

placing the catheter of claim 23 at the site; and

releasing the biodegradable polymer at the site.

28 . A method of delivering a pharmaceutical composition to a site in a body, the method comprising:

placing a catheter at the site; and releasing the pharmaceutical composition at the site, the pharmaceutical composition comprising about 1 to about 50 wt-% therapeutic agent and about 50 to about 99 wt-% biocompatible solvent;

wherein the therapeutic agent comprises paclitaxel; and the biocompatible solvent comprises glycofurol; and

wherein the biocompatible solvent delivers the therapeutic agent within a tissue.

29 . The method of claim 28 , wherein the therapeutic agent is delivered as a solid or semisolid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: SURMODICS, INC.
To: SURMODICS COATINGS, LLC
Reel/Frame 073928/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2015
From: CHAPPA, RALPH A.
To: SURMODICS, INC. CORPORATION OF THE STATE OF MINNESOTA
Reel/Frame 034991/0841 →